Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Quest for Growth NV Earnings Release 2011

Jan 27, 2012

3991_er_2012-01-27_2cbf6039-d5a6-4c68-8377-d2c73bcfec5b.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Press release Leuven / 26 January 2012 / 5.40 PM

Regulated information. This press release contains information subject to the European transparency requirements imposed on listed companies.

Quest for growth

Privak, fixed capital investment company established under Belgian Law

Schedule for publication

on 26 January 2012:

5.40 PM press release available at www.questforgrowth.com

on 27 January 2012:

11.00 AM press & analyst meeting, Quest Management NV, Lei 19, 3000 Leuven

Annual results Quest for Growth

Key figures:

  • • Return on equity per share: 12 % since 31 December 2010
  • • Net Asset Value per share at December 31st 2011: € 7.90 (December 31st 2010: € 8.99).
  • • Net loss for the fiscal year: € 13,313,623 (- € 1.15 per share) against a profit of € 20,568,083 (+ € 1.74 per share) for the previous fiscal year
  • • Share price at December 31st2011: € 4.75 (December 31st 2010: € 5.31) or a decrease of 10.55 %
  • • Discount of the share price versus Net Asset Value: 39.90 % at December 31st 2011 (40.95 % at December 31st 2010).
  • • One new investment in an unquoted company in 2011: Cartagenia (+ € 625,000) and two co-investments in unquoted companies (Ducatt and EpiGaN) for a total amount of € 1,074,527
  • • IPO Sphere Medical Ltd. on 17 November 2011

A series of unexpected events had a negative impact on the economy and on the financial markets in 2011. The earthquake in Japan and especially the subsequent nuclear disaster in Fukushima – which could hardly be controlled - weighed heavily on the worldwide confidence. The Arab Spring, where a number of totalitarian regimes toppled down like dominos, came as a second surprise. The ongoing conflict in Libya, which caused a sudden increase of the oil price, crippled the economic growth, especially in Europe. Apart from geopolitical elements there was also the impact of the debt crisis going off the rails in Europe. The decision process within Euroland was so exasperatingly slow that it could not prevent that, after Greece, Portugal and Ireland were also forced to seek external help for their refinancing needs. In the meantime the confidence in Europe is lost to such an extent that the whole world is focussing on the problem of Euroland, often forgetting that the debt problems of other big countries like the United States, Japan and the UK have similar proportions but are getting far less attention. Even today the confidence in European countries as well as in European financial institutions remains extremely shaky.

In this awkward financial economic climate, several of our portfolio companies performed less well. The quoted companies suffered from the deterioration of the European stock markets. Rapidly growing small & midcaps – those companies on which Quest for Growth primarily focuses – were hit even harder. In the unquoted portfolio the impact was at least as big: new companies had to thoroughly review their business plan because a fast development in a stagnating world proved unfeasible. The companies in need of capital were confronted with a strongly shrinking venture capital market and a considerable deterioration of valuations.

In the past fiscal year Quest for Growth invested in three new unquoted companies:

Through last year's co-investment agreement with the Capricorn Cleantech Fund an investment was made in February in Ducatt NV, a new company in the Capricorn Cleantech Fund portfolio. Ducatt is a Belgian company and a spin out of Emgo NV, a 50/50 joint venture between Osram and Philips Lighting. From the existing company specialised in the production of glass balloons for light bulbs and for glass tubes, the balloon factory is being split off and converted to a high-quality production facility for speciality glass for photovoltaic applications.

Through the same co-investment agreement an investment was made in June in EpiGaN, a spin-off of Imec, aiming to start up the production of GaN-on-silicon. GaN-on-Si (in full: gallium nitrideon-silicon) is considered to be a key technology in the sector of renewable energy. Think about more efficient power supplies or inverters for solar energy and greener transportation technologies with a smaller ecological footprint.

Finally € 1.25 million was invested in Cartagenia in September. Cartagenia is a spin off company from K.U.L., the University of Leuven, developing and marketing software for the worldwide market of genetic labs. This investment was split in two equal tranches of which one was paid immediately.

In one existing portfolio company, Prosonix Ltd., Quest for Growth made a follow-investment of £ 652,563 (€ 728,342), participating in a new financing round. In view of the higher valuation used for this financing round, Quest for Growth booked an unrealised capital gain. Prosonix Ltd is the world leader in the domain of particle engineering for the benefit of the pharmaceutical industry.

One company from the unquoted portfolio successfully completed an IPO in the course of the year. Sphere Medical has been trading on AIM (Alternative Investment Market) since 17 November. On the day of the IPO the company was valued at 34 million. The shares of Quest for Growth in Sphere Medical are subjected to a soft lock-up agreement of 6 months. Following the IPO Quest for Growth applied, in accordance with its valuation rules, a 9 % discount to the stock price in its books. From the first month following the IPO, the discount will decrease by 1.5 % per month and will have disappeared completely after the end of the soft lock-up agreement.

Three companies from the unquoted portfolio were written off completely during the past fiscal year: Active Circle, Nantofen and Mapper Lithography. In one case a company did not find new funding. For another company it was decided not to take part in a new investment round, as a result of which our position diluted to such an extent that the amounts invested in the company were lost.

In the unquoted portfolio value adjustments for a total of - € 2.3 million were booked in a separate line. These value adjustments were booked mainly out of fear that certain portfolio companies, almost in need of refinancing, will have to go to the market at a lower valuation because of the deteriorating economic situation and the more difficult funding climate that goes with it.

In the portfolio of the venture capital funds a number of exits were made as well. From the portfolio of Carlyle Europe Technology Partners I and the linked co-investment Fund for instance the participation in "the Mill" was sold to Barclays Private Equity at three times the investment cost. Kiwi Ventura Serviços, Quest for Growth's first investment in a venture capital fund, has been wound up completely and disappeared from the portfolio with a positive result over the whole term of the fund.

The Extraordinary General Meeting of March 17th 2011 unanimously approved the two proposals: firstly, the reintroduction of "authorised capital" and secondly, a mandate in favour of the Board of Directors to annul the own shares the Company has repurchased. On June 29 259,305 ordinary shares and the corresponding non-distributable reserves amounting to € 1,594,725.25 were annulled. By reducing the number of shares, the net asset value per share increased by approximately € 0.06.

During the General Assembly four independent directors were appointed. We welcomed Regine Slagmulder (via Regine Slagmulder BVBA), Antoon de Proft (via ADP Vision BVBA), Philippe de Vicq de Cumptich (via Axxis BVBA) and Baron Bernard de Gerlache de Gomery, in replacement of Koenraad Debackere, Johan Tack (via Tacan BVBA) and Count Diego du Monceau de Bergendal (via Bergendal & Co SPRL).

In the fiscal year ending on December 31st 2011, the company booked a loss of € 13,313,623 or € 1.15 per share. At the end of 2011 the Net Asset Value per share amounted to € 7.90 compared to € 8.99 on December 31st 2010. The share price amounted to € 4.75 on 31st December 2011, to compare with € 5,31 at the end of the previous fiscal year.

The Annual General Assembly will be held on 15 March 2012 at 11.00 AM in Leuven.

1. Balance sheet 2011
31 December
2010
31 December
2009
31 December
2008
31 December
2007
31 December
ASSETS
Fixed assets 86,989,456 99,778,377 79,850,099 61,137,896 108,892,469
Formation expenses 0 0 0 0 0
Financial assets 86,898,456 99,778,377 79,850,099 61,137,896 108,892,469
Shares 79,492,057 93,078,608 78,033,562 59,198,500 108,028,068
Amounts receivable 7,497,399 6,699,769 1,816,537 1,939,396 864,401
Current assets 4,203,529 6,298,058 5,713,801 6,535,923 7,606,626
Amounts receivable in more than one
year
0 885,932 0 0 0
Trade receivables 0 0 0 0 0
Other receivables 0 885,932 0 0 0
Amounts receivable within one year 1,165,102 98,934 399,726 235,277 298,014
Trade receivables 0 0 237,256 177 0
Other receivables 1,165,102 98,934 162,470 235,100 298,014
Short term investments 0 1,376,910 3,455,768 816,811 6,870,357
Own shares 0 1,376,910 1,205,768 816,811 1,702,806
Term deposits 0 0 2,250,000 0 5,167,551
Cash at bank and in hand 3,038,427 3,724,105 1,797,803 5,165,410 297,132
Deferred charges and accrued income 31,501 212,177 60,504 318,425 141,123
TOTAL ASSETS 91,224,485 106,076,435 85,563,899 67,673,819 116,499,095
LIABILITIES
Capital and reserves 91,101,307 106,009,655 85,441,572 67,365,307 115,769,735
Issued capital 109,748,742 109,748,742 109,748,742 109,748,742 109,748,742
Reserves 656,423 2,251,148 2,251,148 2,251,148 6,000,000
Reserves not available for distribution 0 1,376,910 1,205,768 816,811 1,702,806
Reserves available for distribution 656,423 874,239 1,045,380 1,434,337 4,297,194
Profit carried forward 0 0 0 0 20,993
Loss carried forward (19,303,859) (5,990,236) (26,558,319) (44,634,583) 0
Amount payable 123,179 66,779 122,328 308,512 729,359
Amounts payable within one year 105,882 66,291 69,648 80,253 729,359
Financial debts 0 0 0 0 0
Trade debts
Taxes
55,358
432
7,865
70
42
72
0
178
0
420
Dividends to be paid for the fiscal year 0 0 0 0 600,394
Other amounts payable 50,092 58,356 69,534 80,075 128,546
Accrued charges and deferred income 17,297 488 52,679 228,259 0
TOTAL LIABILITIES 91,224,485 106,076,435 85,563,899 67,673,819 116,499,095
2. Income statement Fiscal year
2011
Fiscal year
2010
Fiscal year
2009
Fiscal year
2008
Fiscal year
2007
Operating income and charges
Gross operating income (13,327,578) 21,373,611 19,136,134 (45,903,202) 3,096,848
Realised gains/losses on shares 1,975,022 14,229,612 (9,073,057) (7,910,960) 3,489,436
Unrealised gains/losses on shares (15,131,517) 7,108,393 28,305,578 (38,451,622) (1,333,413)
Result from option transactions 60,200 254,920 54,090 68,553 (16,463)
Realised results from Forward currency
rate agreements
(37,391) (457,777) (326,057) 752,579 824,850
Unrealised results from Forward
currency rate agreements
(193,893) 238,462 175,579 (361,752) 132,438
Depreciation and other amounts
written off
0 0 0 0 0
Other operating charges (1,904,226) (1,973,725) (2,281,376) (2,688,514) (2,616,901)
Management fee (1,500,000) (1,610,959) (1,950,000) (2,276,684) (2,156,217)
Custodian fee (45,323) (43,940) (29,871) (43,820) (67,015)
Statutory Auditors fee (11,680) (9,183) (12,047) (9,680) (20,933)
Printing and publication costs (76,974) (64,155) (68,663) (122,038) (148,219)
Annual tax on Collective Investment
schemes
(84,808) (67,763) (53,892) (92,616) (76,754)
Directors fees (93,730) (72,398) (68,719) (53,350) (53,140)
Advisory fees (17,852) (34,683) (22,219) (14,731) (22,024)
Accountancy (0) (0) (0) (0) (16,200)
Others (73,859) (70,602) (75,966) (75,595) (56,399)
Operating Profit/Loss (15,231,804) 19,399,928 16,854,758 (48,591,716) 479,947
Financial income 1,770,100 1,394,583 1,025,963 1,621,451 1,527,626
Financial charges 148,442 (226,358) 195,616 (1,434,317) (1,386,901)
Amounts written off own shares* 217,816 171,141 388,957 (1,280,790) (153,548)
Capital increase costs (0) (0) (0) (0) (698,722)
Others (69,373) (397,350) (193,341) (153,527) (534,631)
Profit/Loss on ordinary activities,
before taxes
(13,313,262) 20,568,153 18,076,337 (48,404,582) 620,672
Income taxes (362) (70) (72) 154 (97)
Profit/Loss for the period (13,313,623) 20,568,083 18,076,265 (48,404,428) 620,575

* withdrawals

3. Profit distribution Fiscal year
2011
Fiscal year
2010
Fiscal year
2009
Fiscal year
2008
Fiscal year
2007
Profit to be appropriated 621.387
Loss to be appropriated (19,303,859) (5,990,236) (26,558,319) (48,383,435)
Profit to be appropriated for the period 20,568,083 18,076,265 620,575
Loss to be appropriated for the period (13,313,623) (48,404,428)
Profit/loss brought forward (5,990,236) (26,558,319) (44,634,583) 20,993 812
Transfers from capital and reserves 3,748,852
From reserves 3,748,852
Transfers to capital and reserves
To other reserves
Profit/loss to be carried forward (19,303,859) (5,990,236) (26,558,319) 44,634,584 (20,993)
Profit to be carried forward (20,993)
Loss to be carried forward (19,303,859) (5,990,236) (26,558,319) 44,634,584
Distribution of profit (600,394)
Dividends 600,394

4. Off balance sheet positions

4.1. Commitments Commitments in
currency
Currency Commitments in €
31/12/2011
Commitments in €
31/12/2010
Capricorn Cleantech Co-investments 1,500,000 1,500,000 0
Capricorn Cleantech Fund 675,000 675,000 1,125,000
Capricorn Health-tech Fund 11,250,000 11,250,000 11,250,000
Carlyle Europe Technology Partners I 377,944 377,944 373,086
Carlyle Europe Technology Partners II 1,339,098 1,339,098 2,535,665
Cartagenia 625,001 625,001 0
Life Sciences Partners III 114,219 114,219 196,548
Life Sciences Partners IV 1,213,575 1,213,575 1,717,779
Schroder Ventures International Life
Sciences Fund II
19,953 \$ 15,421 14,933
Ventech Capital 2 305,571 305,571 305,571
Vertex III 166,475 \$ 128,661 320,448
Total: 17,544,490 17,839,030

4.2. Forward Currency Rate Agreements

Value date Counterparty Quest for Growth buys Quest for Growth sells
31/01/2012 Dexia Bank € 2,983,293.56 £ 2,500,000
31/01/2012 KBC Bank € 2,983,222.36 £ 2,500,000
31/01/2012 Dexia Bank € 1,780,874.95 \$ 2,300,000
31/01/2012 KBC Bank € 2,711,444.23 \$ 3,500,000

5. Report of the statutory auditor

The statutory auditor, Klynveld Peat Marwick Goerdeler Bedrijfsrevisoren – Réviseurs d'Entreprises, represented by Mr. Erik Clinck, has issued an unqualified audit opinion on the financial statements of the fiscal year 2011, with explicative paragraph (confirming that the financial statements have been drawn up in the assumption of going concern) and has confirmed that the accounting data included in this annual announcement does not include any apparent inconsistencies with the financial statements.

The annual financial report including the audited annual accounts, the annual report, the statement on the true and fair view of the annual accounts and the fair overview in the annual report by the responsible persons and the report of the Statutory Auditor shall be available as from February 14th 2012, on request at the registered office: Lei 19 box 3, 3000 Leuven, Belgium.

QUEST FOR GROWTH NV Privak, fixed capital investment company established under Belgian Law Lei 19, box 3 B-3000 Leuven - Phone: +32 (0)16 28 41 28 - Fax: +32 (0)16 28 41 29